Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;8(8):e012799.
doi: 10.1136/bmjgh-2023-012799.

Is neglect of self-clearance biasing TB vaccine impact estimates?

Affiliations

Is neglect of self-clearance biasing TB vaccine impact estimates?

Danny Scarponi et al. BMJ Glob Health. 2023 Aug.

Abstract

Background: Mathematical modelling has been used extensively to estimate the potential impact of new tuberculosis vaccines, with the majority of existing models assuming that individuals with Mycobacterium tuberculosis (Mtb) infection remain at lifelong risk of tuberculosis disease. Recent research provides evidence that self-clearance of Mtb infection may be common, which may affect the potential impact of new vaccines that only take in infected or uninfected individuals. We explored how the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India.

Methods: For both countries, we calibrated a tuberculosis model to a scenario without self-clearance and to various scenarios with self-clearance. To account for the current uncertainty in self-clearance properties, we varied the rate of self-clearance, and the level of protection against reinfection in self-cleared individuals. We introduced potential new vaccines in 2025, exploring vaccines that work in uninfected or infected individuals only, or that are effective regardless of infection status, and modelling scenarios with different levels of vaccine efficacy in self-cleared individuals. We then estimated the relative disease incidence reduction in 2050 for each vaccine compared with the no vaccination scenario.

Findings: The inclusion of self-clearance increased the estimated relative reductions in incidence in 2050 for vaccines effective only in uninfected individuals, by a maximum of 12% in China and 8% in India. The inclusion of self-clearance increased the estimated impact of vaccines only effective in infected individuals in some scenarios and decreased it in others, by a maximum of 14% in China and 15% in India. As would be expected, the inclusion of self-clearance had minimal impact on estimated reductions in incidence for vaccines that work regardless of infection status.

Interpretations: Our work suggests that the neglect of self-clearance in mathematical models of tuberculosis vaccines does not result in substantially biased estimates of tuberculosis vaccine impact. It may, however, mean that we are slightly underestimating the relative advantages of vaccines that work in uninfected individuals only compared with those that work in infected individuals.

Keywords: Mathematical modelling; Tuberculosis; Vaccines.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Diagram of the model structure showing parts of TB natural history related to infection and self-clearance in detail. : rate of self-clearance from Infection-Slow Early to Uninfected-Cleared Late. The full model structure showing the disease and treatment compartments, is shown in Supplementary Material, Section A. TB, tuberculosis.
Figure 2
Figure 2
Proportion of individuals in each natural history state and distribution of flows into Infection-Fast in 2025 for different baseline scenarios in China, averaged across model runs. In scenarios with self-clearance, when the rate of self-clearance or the level of protection in Uninfected-Cleared individuals are not indicated, they are fixed at their mid value.
Figure 3
Figure 3
Relative disease incidence reduction (%) in 2050 compared to a scenario with no vaccination, when each of the three self-clearance characteristics is varied separately for no current infection vaccines and current infection vaccines (China on the left, India on the right). For each plot, the two unshown characteristics are fixed to their mid value. The height of the columns show the median percentage reduction in incidence in 2050 compared to the scenario where no vaccine is implemented, with vertical bars indicating the 95% confidence interval. The numbers on top of each column correspond to the relative change in disease incidence reduction compared to the no self-clearance scenario. NCI: no current infection, CI: current infection, POI: prevention of infection, POD: prevention of disease, POID: prevention of infection and disease. CI, current infection; NCI, no CI; POD, prevention of disease; POI, prevention of infection; POID, POI and disease.
Figure 4
Figure 4
Relative disease incidence reduction (%) in 2050 compared to a scenario with no vaccination, obtained by exploring all possible combinations of the extreme values (minimum and maximum) of the three self-clearance characteristics (self-clearance rate, level of natural protection and vaccine efficacy in self-cleared individuals), for no current infection vaccines and current infection vaccines (China on the left, India on the right). The height of the columns show the median percentage reduction in incidence in 2050 compared to the scenario where no vaccine is implemented, with vertical bars indicating the 95% confidence interval. The numbers on top of each column correspond to the relative change in disease incidence reduction compared to the no self-clearance scenario. For no current infection vaccines, the yellow columns are missing in China, as no explored scenario resulted in a decreased vaccine impact. NCI: no current infection, CI: current infection, POI: prevention of infection, POD: prevention of disease, POID: prevention of infection and disease. CI, current infection; NCI, no CI; POD, prevention of disease; POI, prevention of infection; POID, POI and disease.

Update of

References

    1. World Health Organization . Global TB report 2022; 2022.
    1. Martinez L, Cords O, Liu Q, et al. . Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. Lancet Glob Health 2022;10:e1307–16. 10.1016/S2214-109X(22)00283-2 - DOI - PMC - PubMed
    1. Schrager LK, Harris RC, Vekemans J. Research and development of new tuberculosis vaccines: a review. F1000Res 2019;7:1732. 10.12688/f1000research.16521.2 - DOI - PMC - PubMed
    1. Tait DR, Hatherill M, Van Der Meeren O, et al. . Final analysis of a trial of M72/As01 E vaccine to prevent tuberculosis. N Engl J Med 2019;381:2429–39. 10.1056/NEJMoa1909953 - DOI - PubMed
    1. Nemes E, Geldenhuys H, Rozot V, et al. . Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med 2018;379:138–49. 10.1056/NEJMoa1714021 - DOI - PMC - PubMed

Publication types

Substances